Latest Bioanalytical Systems (BASI) Headlines BASi

New Post Public Reply Private Reply Replies (0) Message Board

Mar 12, 2014 at 6:23 PM

Latest Bioanalytical Systems (BASI) Headlines

BASi Reports First Quarter Results
Business Wire - Thu Feb 13, 7:00AM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced financial results for the first quarter of fiscal 2014.

Bioanalytical Systems to Release First Quarter Fiscal 2014 Results on Thursday, February 13, 2014; Conference Call & Webcast Set for 11:00 a.m. EST
GlobeNewswire - Wed Feb 05, 7:00AM CST
Bioanalytical Systems, Inc. (Nasdaq:BASI) will release financial results for the first quarter of fiscal 2014 ended December 31, 2013 at approximately 8:30 a.m. EST on Thursday, February 13, 2014. BASi has scheduled a conference call at 11:00 a.m. EST that morning to discuss its results for the quarter. To participate in the call, dial 800 299.9630, passcode #66359984.

Bioanalytical Systems, Inc. to Present at the 10th Annual Noble Financial Capital Markets Equity Conference Wednesday, January 22, 2014 at 10:00 a.m. EST
Business Wire - Tue Jan 14, 11:31AM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will make a presentation at the Tenth Annual Noble Financial Capital Markets Equity Conference on Wednesday, January 22, 2014 at 10:00 a.m. EST in Room 1 at the Club Med in Sandpiper Bay, Florida.

Nasdaq stocks posting largest volume increases
AP - Tue Dec 24, 4:53PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

BASi Reports Profitable Fourth Quarter and Fiscal 2013
Business Wire - Tue Dec 24, 6:30AM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced financial results for the fourth quarter and fiscal 2013, highlighted by net income of $252,000, or $0.03 per diluted share, for the fourth quarter and $773,000, or $0.09 per diluted share, for the year. This compares to net losses of $2,696,000, or $0.36 per share and $6,317,000, or $0.88 per share, for the fourth quarter and fiscal 2012.

Bioanalytical Systems Reschedules Fourth Quarter & Fiscal 2013 Earnings Release to Tuesday, December 24, 2013; Conference Call & Webcast Set For 11:00 a.m. EST
Business Wire - Thu Dec 19, 6:00AM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) has rescheduled the release of financial results for the fourth quarter and fiscal 2013 ended September 30, 2013 to Tuesday, December 24, 2013. BASi has scheduled a conference call at 11:00 a.m. EST that morning to discuss its results for the quarter. To participate in the call, dial 866.825.1709, passcode #95235310.

Bioanalytical Systems to Release Fourth Quarter & Fiscal 2013 Results on Thursday, December 19, 2013; Conference Call & Webcast Set for 11:00 a.m. EST
GlobeNewswire - Thu Dec 12, 11:09AM CST
Bioanalytical Systems, Inc. (Nasdaq:BASI) will release financial results for the fourth quarter and fiscal 2013 ended September 30, 2013 at approximately 8:30 a.m. EST on Thursday December 19, 2013. BASi has scheduled a conference call at 11:00 a.m. EST that morning to discuss its results for the quarter. To participate in the call, dial 866.825.1709, passcode #95235310.

BASi Announces Extension of Mortgage Maturity
Business Wire - Mon Nov 04, 7:30AM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it has negotiated a twelve month extension, until October 31, 2014, on the maturity of its $5,255,000 mortgage that was originally scheduled to mature on October 31, 2013.

BASi Reports Profitable Third Quarter
Business Wire - Fri Oct 18, 7:30AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced financial results for the third quarter and first nine months of fiscal 2013.

BASi enters into Preferred Provider Agreement with G1 Therapeutics
M2 - Thu Oct 17, 5:20AM CDT
BASi (Bioanalytical Systems Inc) (Nasdaq:BASI) announced on Wednesday that it has entered into a Preferred Provider Agreement (PPA) with G1 Therapeutics, a developer of small molecule therapeutics to protect bone marrow from damage due to chemotherapy or radiation.

Bioanalytical Systems to Release Third Quarter Results Friday, October 18, 2013; Conference Call & Webcast Set For 11:00 a.m. EDT
GlobeNewswire - Wed Oct 16, 12:31PM CDT
Bioanalytical Systems, Inc. (Nasdaq:BASI) will release financial results for the third quarter ended June 30, 2013 at approximately 8:30 a.m. EDT on Friday, October 18, 2013. BASi has scheduled a conference call at 11:00 a.m. EDT that morning to discuss its results for the quarter. To participate in the call, dial 877.474.9502, passcode #70599127.

BASi Signs Preferred Provider Agreement with G1 Therapeutics.
Business Wire - Wed Oct 16, 10:28AM CDT
BASi (Bioanalytical Systems, Inc.) (NASDAQ: BASI) announced today that it has entered into a Preferred Provider Agreement (PPA) with G1 Therapeutics, a privately held company that develops small molecule therapeutics to protect bone marrow from damage due to chemotherapy or radiation. Under the agreement, BASi will become the preferred provider of preclinical services, including toxicology, bioanalytical and analytical testing, to support G1's drug development programs.

BASi Files Amended Form 10-K and 10-Q with the SEC
Business Wire - Fri Oct 11, 3:05PM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it has filed amended quarterly and annual reports with the SEC, including Form 10-K/A for the fiscal years ended September 30, 2011 and 2012, Form 10-Q/A for the three months ended December 31, 2011 and 2012, and Form 10-Q/A for the three and six months ended March 31, 2012 and 2013.

BASi Files Form 8K Notice of Non-Compliance with a Continued Listing Rule Non-Reliance on Previously Issued Financial Statements
Business Wire - Wed Aug 21, 5:00PM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that on August 15, 2013, the Company received a letter from the Nasdaq Listing Qualifications Department stating that the Company no longer complies with the Listing Rules for continued listing of the Company's common shares on the Nasdaq Capital Market since the Company has not yet filed its Form 10-Q for the period ended June 30, 2013 with the Securities and Exchange Commission.

BASi Files Form 12b-25
Business Wire - Wed Aug 14, 8:00AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it is unable to file its Form 10-Q for the three and nine months ended June 30, 2013, as it works to resolve a complex accounting issue relating to the accounting treatment for its outstanding warrants. As a result, the announcement of BASi's third quarter and nine month financial results and the conference call scheduled for today have been postponed.

Bioanalytical Systems to Release Third Quarter Results Wednesday, August 14, 2013; Conference Call & Webcast Set for 11:00 a.m. EDT
GlobeNewswire - Wed Aug 07, 7:30AM CDT
Bioanalytical Systems, Inc. (Nasdaq:BASI) will release financial results for the third quarter ended June 30, 2013 at approximately 8:30 a.m. EDT on Wednesday, August 14, 2013. BASi has scheduled a conference call at 11:00 a.m. EDT that morning to discuss its results for the quarter. To participate in the call, dial 877.415.3178, passcode #76846443.

BASi Reports Second Quarter Results
Business Wire - Wed May 15, 7:30AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced financial results for the second quarter and first half of fiscal 2013.

BASi Launches Innovative Glucose Monitoring Project With Pinnacle Technology
Business Wire - Thu May 02, 7:30AM CDT
BASi (Bioanalytical Systems, Inc.) (NASDAQ: BASI) announced today that it is collaborating with Pinnacle Technology Inc. in proof-of-concept studies combining BASi's Culex(R) NxT automated blood sampling system with Pinnacle's glucose sensor to create an innovative new option for high quality data collection for diabetes and other glucose research.

Inotiv, Inc. (NOTV) Stock Research Links

NOTV Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...